Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Total Ad Campaign Aims To Counter Crest Pro-Health Claims

This article was originally published in The Tan Sheet

Executive Summary

Colgate will launch new advertisements for Colgate Total toothpaste to respond to direct competition from Procter & Gamble's new Crest Pro-Health toothpaste, according to Colgate-Palmolive President and COO Ian Cook

You may also be interested in...



Colgate on acquisitions

Colgate-Palmolive would "not easily move into" OTC or pharmaceutical categories, CEO Reuben Mark stated during the Sanford Bernstein Strategic Decisions Conference June 1. Colgate has been identified as a potential bidder for Pfizer's Consumer Healthcare unit, which includes the Listerine oral care brand (1"The Tan Sheet" May 29, 2006, p. 6). Pfizer has expressed that it is not interested in selling its brands individually. Separately, Mark noted the firm's advertising spend will be up a record 13%-14% for the full year. Colgate put $297.1 mil. behind its global brands in the first quarter (2"The Tan Sheet" May 15, 2006, p. 11). The company also spent a record amount on advertising last year, with spending up 11.5%, according to the exec...

Colgate Strategic Restructuring Aimed At Boosting Ad Spend, Earnings

Colgate is undertaking a four-year restructuring plan aimed at increasing the company's profits by generating annual savings of $250 mil.-$300 mil. after taxes by the fourth year

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel